Initial distribution to hospitals and patients expected to begin on July 31st BASKING RIDGE, N.J. , July 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced more information about availability, distribution and pricing
Paper supports use of nVNS as a front-line therapy for acute and preventative treatment of cluster headache and as an effective option for the treatment of migraine headache BASKING RIDGE, N.J. , July 28, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
BASKING RIDGE, N.J. , July 16, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on July 14, 2020 , the company’s cash was incorrectly stated as being as of the end of the first quarter. Note that the company ended the second quarter of 2020 with cash, cash equivalents and
BASKING RIDGE, N.J. , July 14, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited financial guidance for the second quarter and full year 2020.
Intended use allows gammaCore Sapphire CV use at home or in a healthcare setting BASKING RIDGE, N.J. , July 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the FDA has issued an Emergency Use Authorization (EUA)
BASKING RIDGE, N.J. , July 09, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger , Chief Executive Officer, will participate in three upcoming investor conferences: Maxim Group/M-Vest COVID-19 Virtual
BASKING RIDGE, N.J. , May 29, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger , Chief Executive Officer, will be available at Little Grapevine™ (
Generated first quarter revenue of $734,000 Secured FDA clearance of gammaCore ™ (nVNS) label expansion for migraine prevention Announced initiatives to support the potential use of nVNS for the treatment of symptoms associated with COVID-19 Company to host conference call and webcast today, May
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , May 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2020 after the close of
Randomized controlled investigator-initiated trial (IIT) of non-invasive vagus nerve stimulation (nVNS) therapy currently enrolling COVID-19 patients in Spain Peer-reviewed paper, “Use of Non-Invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated with COVID-19: A Theoretical